Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haloeye PG is an ophthalmic lubricant solution developed and marketed by Eyekare Kilitch. It is a fixed-dose combination of polyethylene glycol 400 (0.4% w/v) and propylene glycol (0.3% w/v). The eye drops are indicated for the temporary relief of burning, irritation, and discomfort caused by dry eyes. By acting as demulcents, the active ingredients mimic natural tears to lubricate and protect the ocular surface, helping to restore moisture and reduce redness and swelling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 400 + propylene glycol (Kilitch Drugs (India) Ltd).